0001140361-18-017371.txt : 20180405 0001140361-18-017371.hdr.sgml : 20180405 20180405112213 ACCESSION NUMBER: 0001140361-18-017371 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20180405 DATE AS OF CHANGE: 20180405 EFFECTIVENESS DATE: 20180405 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Eleven Biotherapeutics, Inc. CENTRAL INDEX KEY: 0001485003 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 262025616 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-309400 FILM NUMBER: 18739715 BUSINESS ADDRESS: STREET 1: 245 FIRST STREET STREET 2: SUITE 1800 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-444-8550 MAIL ADDRESS: STREET 1: 245 FIRST STREET STREET 2: SUITE 1800 CITY: CAMBRIDGE STATE: MA ZIP: 02142 D 1 primary_doc.xml X0708 D LIVE 0001485003 Eleven Biotherapeutics, Inc. 245 FIRST STREET SUITE 1800 CAMBRIDGE MA MASSACHUSETTS 02142 617-444-8550 DELAWARE None None Corporation true Stephen A. Hurly 245 First Street, Suite 1800 Cambridge MA MASSACHUSETTS 02142 Executive Officer Director President and Chief Executive Officer Richard F. Fitzgerald 245 First Street, Suite 1800 Cambridge MA MASSACHUSETTS 02142 Executive Officer Chief Financial Officer, Secretary and Treasurer Wendy L. Dixon 245 First Street, Suite 1800 Cambridge MA MASSACHUSETTS 02142 Director Chairman of the Board of Directors Abbie C. Celniker 245 First Street, Suite 1800 Cambridge MA MASSACHUSETTS 02142 Director Paul G. Chaney 245 First Street, Suite 1800 Cambridge MA MASSACHUSETTS 02142 Director Leslie Dan 245 First Street, Suite 1800 Cambridge MA MASSACHUSETTS 02142 Director Jay S. Duker 245 First Street, Suite 1800 Cambridge MA MASSACHUSETTS 02142 Director Barry J. Gertz 245 First Street, Suite 1800 Cambridge MA MASSACHUSETTS 02142 Director Jane V. Henderson 245 First Street, Suite 1800 Cambridge MA MASSACHUSETTS 02142 Director Daniel S. Lynch 245 First Street, Suite 1800 Cambridge MA MASSACHUSETTS 02142 Director Biotechnology Decline to Disclose 06b false 2018-03-21 false true true true false 0 Laidlaw & Company (UK) Ltd. 119037 None None 546 Fifth Avenue New York NY NEW YORK 10036 CA CALIFORNIA CT CONNECTICUT IL ILLINOIS MA MASSACHUSETTS MD MARYLAND NJ NEW JERSEY NY NEW YORK OR OREGON TX TEXAS false 996016 996016 0 false 10 36093 30852 The Company agreed to pay H.C. Wainwright & Co., LLC a portion of the fees which would have otherwise been payable to Laidlaw & Company (UK) Ltd., as a finders' fee in connection with the issuance of the securities under the purchase agreement. 0 false Eleven Biotherapeutics, Inc. /s/ Stephen A. Hurly Stephen A. Hurly President and Chief Executive Officer 2018-04-05